medigraphic.com
ISSN 2500-7106 (Digital)
ISSN 0123-2576 (Impreso)
Medicina & Laboratorio

2022, Número 3

<< Anterior Siguiente >>

Medicina & Laboratorio 2022; 26 (3)


Alteraciones hematológicas como consecuencia de COVID-19 y sus vacunas

Vizcaíno-Carruyo JC, Toro-Montoya AI

Idioma: Español
Referencias bibliográficas: 58
Paginas: 219-236
Archivo PDF: 472.91 Kb.


RESUMEN

El virus SARS-CoV-2 continúa infectando a millones de individuos en el mundo. Aunque los síntomas más frecuentes observados en los pacientes con COVID-19 son fiebre, fatiga y tos, en los casos severos la hipercoagulabilidad y la inflamación son dos condiciones que pueden producir complicaciones y causar daño en órganos, poniendo en riesgo la vida del paciente. Con el fin de clasificar a los pacientes durante el triaje, se han explorado diferentes marcadores hematológicos, incluidos el recuento de plaquetas, linfocitos y eosinófilos, y la relación neutrófilos/ linfocitos, entre otros. Por su parte, para la evaluación de las coagulopatías, se vienen determinando marcadores como el dímero D y el fibrinógeno. En esta revisión se abordan las coagulopatías y los parámetros hematológicos en pacientes con COVID-19, al igual que las anormalidades en la coagulación como la trombocitopenia trombótica inmune inducida por las vacunas contra el SARS-CoV-2.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Mendiola-Pastrana IR, López-Ortiz E, Río de laLoza-Zamora JG, González J, Gómez-García A,López-Ortiz G. SARS-CoV-2 variants and clinicaloutcomes: A systematic review. Life 2022;12:170.https://doi.org/10.3390/life12020170.

  2. Tiecco G, Storti S, Degli Antoni M, Focà E,Castelli F, Quiros-Roldan E. Omicron geneticand clinical peculiarities that may overturnSARS-CoV-2 pandemic: A literature review. IntJ Mol Sci 2022;23. https://doi.org/10.3390/ijms23041987.

  3. Bahraini M, Dorgalaleh A. The impact ofSARS-CoV-2 infection on blood coagulationand fibrinolytic pathways: a review ofprothrombotic changes caused by COVID-19.Semin Thromb Hemost 2022;48:19-30. https://doi.org/10.1055/s-0041-1736166.

  4. Blomme S, Smets L, Van Ranst M, Boeckx N,Van Laer C. The influence of COVID-19 on routinehematological parameters of hospitalized patients.Acta Clin Belg 2022;77:241-246. https://doi.org/10.1080/17843286.2020.1814649.

  5. Dubey DB, Mishra S, Reddy HD, Rizvi A, AliW. Hematological and serum biochemistryparameters as a prognostic indicator of severallyill versus mild COVID-19 patients: A studyfrom tertiary hospital in North India. Clin EpidemiolGlob Health 2021;12:100806. https://doi.org/10.1016/j.cegh.2021.100806.

  6. Yang H, Xu Y, Li Z, Yan L, Wang J, Liao P. Theclinical implication of dynamic hematologicalparameters in COVID-19: A retrospectivestudy in Chongqing, China. Int J Gen Med2021;14:4073-4080. https://doi.org/10.2147/ijgm.S321292.

  7. Ghazanfari T, Salehi MR, Namaki S, ArabkheradmandJ, Rostamian A, RajabniaChenary M, et al. Interpretation of hematological,biochemical, and immunological findingsof COVID-19 disease: Biomarkers associatedwith severity and mortality. Iran J AllergyAsthma Immunol 2021;20:46-66. https://doi.org/10.18502/ijaai.v20i1.5412.

  8. Elkhalifa AME, Elderdery AY, Al Bataj IA,Tamomh AG, Alyami MM, Almakrami HA,et al. Hematological findings among COVID-19 patients attending King Khalid Hospitalat Najran, Kingdom of Saudi Arabia. BiomedRes Int 2022;2022:4620037. https://doi.org/10.1155/2022/4620037.

  9. Al-Saadi E, Abdulnabi MA. Hematologicalchanges associated with COVID-19 infection.J Clin Lab Anal 2022;36:e24064. https://doi.org/10.1002/jcla.24064.

  10. Suryawanshi SY, Priya S, Sinha SS, Soni S,Haidry N, Verma S, et al. Dynamic profile andclinical implications of hematological and immunologicalparameters in COVID-19 patients.A retrospective study. J Family Med Prim Care2021;10:2518-2523. https://doi.org/10.4103/jfmpc.jfmpc_2400_20.

  11. Taj S, Kashif A, Arzinda Fatima S, Imran S,Lone A, Ahmed Q. Role of hematological parametersin the stratification of COVID-19 diseaseseverity. Ann Med Surg (Lond) 2021;62:68-72.https://doi.org/10.1016/j.amsu.2020.12.035.

  12. Saurabh A, Dey B, Raphael V, Barman B, DevP, Tiewsoh I, et al. Evaluation of hematologicalparameters in predicting intensive care unitadmission in COVID-19 patients. SN ComprClin Med 2022;4:39. https://doi.org/10.1007/s42399-021-01115-8.

  13. Damiati LA, Bahlas S, Aljohaney A, BawazirY, Mustafa M, Denetiu I, et al. Implications ofSARS-CoV-2 infection on the clinical, hematological,and inflammatory parameters in COVID-19 patients: A retrospective cross-sectionalstudy. J Infect Public Health 2022;15:214-221.https://doi.org/10.1016/j.jiph.2021.12.013.

  14. Szklanna PB, Altaie H, Comer SP, Cullivan S,Kelliher S, Weiss L, et al. Routine hematologicalparameters may be predictors of COVID-19severity. Front Med (Lausanne) 2021;8:682843.https://doi.org/10.3389/fmed.2021.682843.

  15. Alkan G, Sert A, Emiroglu M, Tuter Oz SK, VatansevH. Evaluation of hematological parametersand inflammatory markers in children withCOVID-19. Ir J Med Sci 2021:1-9. https://doi.org/10.1007/s11845-021-02762-5.

  16. Ötiken-Arıkan K, Şahinkaya Ş, BöncüoğluE, Kıymet E, Cem E, Akaslan-Kara A, et al.Can hematological findings of COVID-19in pediatric patients guide physicians regardingclinical severity? Turk J Haematol2021;38:243-245. https://doi.org/10.4274/tjh.galenos.2021.2021.0157.

  17. Shokri P, Golmohammadi S, Noori M, NejadghaderiSA, Carson-Chahhoud K, SafiriS. The relationship between blood groups andrisk of infection with SARS-CoV-2 or developmentof severe outcomes: A review. Rev MedVirol 2022;32:e2247. https://doi.org/10.1002/rmv.2247.

  18. Saleh M, Alkofide A, Alshammari A, SiddiquiK, Owaidah T. Changes in hematological,clinical and laboratory parameters for childrenwith covid-19: Single-center experience.J Blood Med 2021;12:819-826. https://doi.org/10.2147/jbm.S321372.

  19. Bonaventura A, Vecchié A, Dagna L, MartinodK, Dixon DL, Van Tassell BW, et al. Endothelialdysfunction and immunothrombosisas key pathogenic mechanisms in COVID-19.Nat Rev Immunol 2021;21:319-329. https://doi.org/10.1038/s41577-021-00536-9.

  20. Abrignani MG, Murrone A, De Luca L, RonconL, Di Lenarda A, Valente S, et al. COVID-19,vaccines, and thrombotic events: A narrativereview. J Clin Med 2022;11. https://doi.org/10.3390/jcm11040948.

  21. Chen AT, Wang CY, Zhu WL, Chen W. Coagulationdisorders and thrombosis in COVID-19 patients and a possible mechanisminvolving endothelial cells: A review. Aging Dis2022;13:144-156. https://doi.org/10.14336/ad.2021.0704.

  22. Sbirkov Y, Dzharov V, Todorova K, HayrabedyanS, Sarafian V. Endothelial inflammation anddysfunction in COVID-19. Vasa 2022;51:62-70.https://doi.org/10.1024/0301-1526/a000991.

  23. Cryer MJ, Farhan S, Kaufmann CC, Jäger B,Garg A, Krishnan P, et al. Prothrombotic milieu,thrombotic events and prophylactic anticoagulationin hospitalized COVID-19 positivepatients: A review. Clin Appl Thromb Hemost2022;28:10760296221074353. https://doi.org/10.1177/10760296221074353.

  24. Sastry S, Cuomo F, Muthusamy J. COVID-19and thrombosis: The role of hemodynamics.Thromb Res 2022;212:51-57. https://doi.org/10.1016/j.thromres.2022.02.016.

  25. Iba T, Warkentin TE, Thachil J, Levi M, Levy JH.Proposal of the definition for COVID-19-associatedcoagulopathy. J Clin Med 2021;10:191.https://doi.org/10.3390/jcm10020191.

  26. Teimury A, Khameneh MT, Khaledi EM. Majorcoagulation disorders and parameters inCOVID-19 patients. Eur J Med Res 2022;27:25.https://doi.org/10.1186/s40001-022-00655-6.

  27. Ulanowska M, Olas B. Modulation of hemostasisin COVID-19; blood platelets may be importantpieces in the COVID-19 puzzle. Pathogens(Basel, Switzerland) 2021;10:370. https://doi.org/10.3390/pathogens10030370.

  28. Violi F, Pastori D, Cangemi R, Pignatelli P,Loffredo L. Hypercoagulation and antithrombotictreatment in coronavirus 2019: A newchallenge. Thromb Haemost 2020;120:949-956. https://doi.org/10.1055/s-0040-1710317.

  29. Guan W-J, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q,He J-X, et al. Clinical characteristics of coronavirusdisease 2019 in China. N Engl J Med2020;382:1708-1720. https://doi.org/10.1056/NEJMoa2002032.

  30. La Torre G, Marte M, Massetti AP, Carli SM, RomanoF, Mastroianni CM, et al. The neutrophil/lymphocyte ratio as a prognostic factor in COVID-19 patients: a case-control study. Eur RevMed Pharmacol Sci 2022;26:1056-1064. https://doi.org/10.26355/eurrev_202202_28017.

  31. Castillo-Martínez D, Torres Z, Amezcua-Guerra LM, Pineda C. Are antiphospholipidantibodies just a common epiphenomenonor are they causative of immune-mediatedcoagulopathy in COVID-19? Clin Rheumatol2021;40:3015-3019. https://doi.org/10.1007/s10067-021-05724-5.

  32. Favaloro EJ, Henry BM, Lippi G. COVID-19 andantiphospholipid antibodies: Time for a realitycheck? Semin Thromb Hemost 2022;48:72-92.https://doi.org/10.1055/s-0041-1728832.

  33. Xiao M, Zhang Y, Zhang S, Qin X, Xia P,Cao W, et al. Antiphospholipid antibodies incritically ill patients with COVID-19. ArthritisRheumatol 2020;72:1998-2004. https://doi.org/10.1002/art.41425.

  34. Al-Ali D, Elshafeey A, Mushannen M, KawasH, Shafiq A, Mhaimeed N, et al. Cardiovascularand haematological events post COVID-19 vaccination: A systematic review. JCell Mol Med 2022;26:636-653. https://doi.org/10.1111/jcmm.17137.

  35. Klok FA, Pai M, Huisman MV, Makris M. Vaccine-induced immune thrombotic thrombocytopenia.Lancet Haematol 2022;9:e73-e80. https://doi.org/10.1016/s2352-3026(21)00306-9.

  36. Mohseni-Afshar Z, Babazadeh A, JanbakhshA, Afsharian M, Saleki K, Barary M, et al.Vaccine-induced immune thrombotic thrombocytopeniaafter vaccination against Covid-19:A clinical dilemma for clinicians and patients.Rev Med Virol 2022;32:e2273. https://doi.org/10.1002/rmv.2273.

  37. Iba T, Levy JH. Thrombosis and thrombocytopeniain COVID-19 and after COVID-19 vaccination.Trends Cardiovasc Med 2022. https://doi.org/10.1016/j.tcm.2022.02.008.

  38. Arepally GM, Ortel TL. Vaccine-induced immunethrombotic thrombocytopenia: what we knowand do not know. Blood 2021;138:293-298.https://doi.org/10.1182/blood.2021012152.

  39. Bussel JB, Connors JM, Cines DB, Dunbar CE,Michaelis LC, Baumann-Kreuziger L, et al.Vaccine-induced Immune thrombotic thrombocytopenia.Washington: American Societyof Hematology; 2022. Acceso 30 de marzo de2022. Disponible en https://www.hematology.org/covid-19/vaccine-induced-immune-thrombotic-thrombocytopenia.

  40. Ahmed SH, Shaikh TG, Waseem S, Qadir NA,Yousaf Z, Ullah I. Vaccine-induced thromboticthrombocytopenia following coronavirus vaccine:A narrative review. Ann Med Surg (Lond)2022;73:102988. https://doi.org/10.1016/j.amsu.2021.102988.

  41. Bilotta C, Perrone G, Adelfio V, SpatolaGF, Uzzo ML, Argo A, et al. COVID-19vaccine-related thrombosis: A systematic reviewand exploratory analysis. Front Immunol2021;12:729251. https://doi.org/10.3389/fimmu.2021.729251.

  42. Franchini M, Liumbruno GM, Pezzo M. COVID-19 vaccine-associated immune thrombosisand thrombocytopenia (VITT): Diagnosticand therapeutic recommendations for a newsyndrome. Eur J Haematol 2021;107:173-180.https://doi.org/10.1111/ejh.13665.

  43. Calcaterra G, Bassareo PP, Barilla F, RomeoF, Mehta JL. Concerning the unexpectedprothrombotic state following some coronavirusdisease 2019 vaccines. J CardiovascMed (Hagerstown) 2022;23:71-74. https://doi.org/10.2459/jcm.0000000000001232.

  44. Matar RH, Than CA, Nakanishi H, Daniel RS,Smayra K, Sim BL, et al. Outcomes of patientswith thromboembolic events following coronavirusdisease 2019 AstraZeneca vaccination:a systematic review and meta-analysis. BloodCoagul Fibrinolysis 2022;33:90-112. https://doi.org/10.1097/mbc.0000000000001113.

  45. Cauchi M, Ball H, Ben-Shlomo Y, RobertsonN. Interpretation of vaccine associated neurologicaladverse events: a methodological andhistorical review. J Neurol 2022;269:493-503.https://doi.org/10.1007/s00415-021-10747-8.

  46. Afshar ZM, Barary M, Babazadeh A, HosseinzadehR, Alijanpour A, Miri SR, et al. SARSCoV-2-related and Covid-19 vaccine-inducedthromboembolic events: A comparative review.Rev Med Virol 2022:e2327. https://doi.org/10.1002/rmv.2327.

  47. Lippi G, Favaloro EJ. Cerebral venousthrombosis developing after COVID-19 vaccination:VITT, VATT, TTS, and more. SeminThromb Hemost 2022;48:8-14. https://doi.org/10.1055/s-0041-1736168.

  48. Sharifian-Dorche M, Bahmanyar M, Sharifian-Dorche A, Mohammadi P, Nomovi M, MowlaA. Vaccine-induced immune thrombotic thrombocytopeniaand cerebral venous sinus thrombosispost COVID-19 vaccination; a systematicreview. J Neurol Sci 2021;428:117607. https://doi.org/10.1016/j.jns.2021.117607.

  49. Uzun G, Pelzl L, Singh A, Bakchoul T. Immunemediatedplatelet activation in COVID-19 andvaccine-induced immune thrombotic thrombocytopenia.Front Immunol 2022;13:837629.https://doi.org/10.3389/fimmu.2022.837629.

  50. Kashir J, Ambia AR, Shafqat A, Sajid MR,AlKattan K, Yaqinuddin A. Scientific premise forthe involvement of neutrophil extracellular traps(NETs) in vaccine-induced thrombotic thrombocytopenia(VITT). J Leukoc Biol 2022;111:725-734.https://doi.org/10.1002/jlb.5covr0621-320rr.

  51. Simka M. Asociación de las vacunas frente a laCOVID-19 basadas en vectores de adenovirus ytrombosis del seno venoso cerebral: ¿guardanrelación estos episodios con la formación detrampas extracelulares de neutrófilos? Vacunas2022;23:564-567. https://doi.org/10.1016/j.vacun.2021.12.002.

  52. Kheyrandish S, Rastgar A, Arab-Zozani M,Sarab GA. Portal vein thrombosis might developby COVID-19 infection or vaccination: Asystematic review of case-report studies. FrontMed 2021;8:794599. https://doi.org/10.3389/fmed.2021.794599.

  53. de Gregorio C, Colarusso L, Calcaterra G,Bassareo PP, Ieni A, Mazzeo AT, et al. Cerebralvenous sinus thrombosis following COVID-19 vaccination: Analysis of 552 worldwidecases. Vaccines (Basel) 2022;10:232. https://doi.org/10.3390/vaccines10020232.

  54. Elberry MH, Abdelgawad HAH, HamdallahA, Abdella WS, Ahmed AS, Ghaith HS, et al.A systematic review of vaccine-induced thromboticthrombocytopenia in individuals whoreceived COVID-19 adenoviral-vector-basedvaccines. J Thromb Thrombolysis 2022:1-26.https://doi.org/10.1007/s11239-021-02626-w.

  55. Finsterer J. Neurological side effects ofSARS-CoV-2 vaccinations. Acta Neurol Scand2022;145:5-9. https://doi.org/10.1111/ane.13550.

  56. Hafeez MU, Ikram M, Shafiq Z, Sarfraz A,Sarfraz Z, Jaiswal V, et al. COVID-19 vaccineassociatedthrombosis with thrombocytopeniasyndrome (TTS): A systematic review andpost hoc analysis. Clin Appl Thromb Hemost2021;27:10760296211048815. https://doi.org/10.1177/10760296211048815.

  57. Waqar U, Ahmed S, Gardezi S, Tahir MS,Abidin ZU, Hussain A, et al. Thrombosiswith thrombocytopenia syndrome afteradministration of AZD1222 or Ad26.COV2.S vaccine for COVID-19: A systematicreview. Clin Appl Thromb Hemost2021;27:10760296211068487. https://doi.org/10.1177/10760296211068487.

  58. Favaloro EJ, Pasalic L, Lippi G. Review andevolution of guidelines for diagnosis of COVID-19 vaccine induced thrombotic thrombocytopenia(VITT). Clin Chem Lab Med2022;60:7-17. https://doi.org/10.1515/cclm-2021-1039.




2020     |     www.medigraphic.com